Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
The FDA recently approved changes that would make some weight-loss medications more expensive. Former White House press ...
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback